Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA

This article was originally published in The Tan Sheet

Executive Summary

The trade group recommends FDA write a separate proprietary name guidance for OTC drugs. FDA’s draft guidance also renders useless OTC manufacturers’ expertise in conducting tests to determine whether consumers safely self-select nonprescription drugs based on labeling, CHPA says in comments.

You may also be interested in...



Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space

ClariSpray is the same formulation as GSK Consumer Healthcare's Flonase Allergy Relief, but Bayer is not making all of the same claims because OTC Flonase for another year has exclusivity among OTC intranasal corticosteroids for eye-related allergy relief.

Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space

ClariSpray is the same formulation as GSK Consumer Healthcare's Flonase Allergy Relief, but Bayer is not making all of the same claims because OTC Flonase for another year has exclusivity among OTC intranasal corticosteroids for eye-related allergy relief.

Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals

OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS107173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel